Daishin Securities maintained its investment opinion "buy" and target stock price at 95,000 won on the 30th, saying Yuhan Corp. has good performance and good R&D.
Yuhan Corp. posted consolidated sales of 433.3 billion won in the second quarter, up 4.3 percent from a year earlier. Operating profit fell 34.3% to 23.4 billion won.
Operating profit decreased compared to the previous year due to the massive milestone base effect. However, as R&D costs decreased, operating profit exceeded the consensus by 17.7%.
Yuhan Corporation showed even growth in all business sectors in the second quarter. The pharmaceutical business rose 11.5% year-on-year to 317.5 billion won and the living health business sector rose 9.4% to 50.6 billion won. Overseas business also posted sales of 36.6 billion won, up 24.1% from the same period last year.
Daishin Securities analyzed, "We expect the value of the pipeline to rise following the announcement of the results in the second half of 2022.".
Reporter Lee Dong-hoon usinvestmentidea2020@gmail.com
